on ABSCIENCES (EPA:AB)
AB Science Stock Coverage Initiated by Maxim Group with €4 Target Price
AB Science SA has announced that its stock is now covered by Maxim Group, a U.S.-based investment bank. This coverage began with a study titled "Mastering Mast Cell Inhibition for Neurodegenerative Diseases Starting with ALS," recommending a buy rating with a target price of €4.00.
Maxim Group's study highlights masitinib's promising results in treating neurodegenerative diseases. The study emphasizes the positive risk-benefit profile of masitinib, supported by data from progressive multiple sclerosis (MS) and mild Alzheimer's disease (AD), which further validates its neuroprotective potential.
This initiation by Maxim Group adds to the consensus from other financial analysts such as Chardan, In Extenso Finance, and DNA Finance, enriching the analytical coverage of AB Science's stock. This development represents a significant milestone for the company in enhancing its market presence and improving investor confidence.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABSCIENCES news